Skip to Main Content

The Departments of Anesthesiology and Neurology Host: “Perivascular Spaces in the Brain & Contributions to Pathology of Cerebral Small Vessel Disease” on March 24

February 04, 2020

The Departments of Anesthesiology and Neurology host: Perivascular Spaces in the Brain & Contributions to Pathology of Cerebral Small Vessel Disease

Perivascular space and cerebral small vessel disease mini-symposium March 24 in the Brady Memorial Auditorium 1:30-4:30pm

Sponsored by the Leducq Foundation

The panel will feature the following speakers:

  • Keynote Speaker: Joanna M. Wardlaw (Professor of Applied Neuroimaging and Director of Edinburgh Imaging, University of Edinburgh) “Perivascular Spaces in the Brain: Anatomy, Physiology, and Contributions to Pathology of Small Vessel Disease”
  • Jaime Grutzendler, MD (Professor of Neurology and Neuroscience): “Optical Interrogation of Neurovascular and Myelin Pathophysiology in the Live Mammalian Brain”
  • Miriam Treggiari, MD PhD (Professor of Anesthesiology): “Delayed cerebral ischemia in SAH - mechanisms and opportunities for intervention”
  • Keynote Speaker Philip Bath (Professor of Stroke Medicine, University of Nottingham): “Pharmacological treatment and prevention of cerebral small vessel disease: a review of potential interventions”
  • Moderator: Helene Benveniste, MD, PhD (Professor of Anesthesiology)

Contact: Jennifer Vissagio Jennifer.vissagio@yale.edu 203 785 3358

Host Organizations: Anesthesiology and Neurology

Precis: Cerebral small vessel disease (cSVD) are a group of disorders that result from pathological alteration of the small blood vessels in the brain and rank as the most common pathology in vascular dementia. Of the nearly 35-36 million people that are estimated to suffer from dementia worldwide, up to 65% have an cSVD component. Unfortunately, the prevalence of SVD is increasing and effective disease-modifying interventions are yet to be found. In recent years, there has been tremendous growth in new diagnostic information, a greater understanding of cSVD risk factors as well as instigation of new large clinical trials of repurposed drugs in cSVD to prevent dementia and stroke.